These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34161001)

  • 21. Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients.
    Li Y; Wang Y; Li N; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Xu B; Huang J
    Chin Med J (Engl); 2022 Apr; 135(8):988-990. PubMed ID: 35730374
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors].
    El Hazzaz R; Kfoury M; Lavaud P; Marabelle A; Champiat S; Mellas N; Besse B; Massard C; Geraud A
    Bull Cancer; 2021 Jun; 108(6):635-642. PubMed ID: 33888298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.
    Gorbet MJ; Ranjan A
    Pharmacol Ther; 2020 Mar; 207():107456. PubMed ID: 31863820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent progress in immunotherapy for urological cancer.
    Obara W; Kato R; Kato Y; Kanehira M; Takata R
    Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".
    Simonelli M; Persico P; Perrino M; Zucali PA; Navarria P; Pessina F; Scorsetti M; Bello L; Santoro A
    Cancer Treat Rev; 2018 Sep; 69():121-131. PubMed ID: 29966936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photodynamic Therapy and Immune Checkpoint Blockade
    Cramer GM; Moon EK; Cengel KA; Busch TM
    Photochem Photobiol; 2020 Sep; 96(5):954-961. PubMed ID: 32573787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.
    Chen S; Song Z; Zhang A
    Curr Top Med Chem; 2019; 19(3):180-185. PubMed ID: 30854972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
    Noguchi E; Shien T; Iwata H
    Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
    Pearson ADJ; Rossig C; Lesa G; Diede SJ; Weiner S; Anderson J; Gray J; Geoerger B; Minard-Colin V; Marshall LV; Smith M; Sondel P; Bajars M; Baldazzi C; Barry E; Blackman S; Blanc P; Capdeville R; Caron H; Cole PD; Jiménez JC; Demolis P; Donoghue M; Elgadi M; Gajewski T; Galluzzo S; Ilaria R; Jenkner A; Karres D; Kieran M; Ligas F; Lowy I; Meyers M; Oprea C; Peddareddigari VGR; Sterba J; Stockman PK; Suenaert P; Tabori U; van Tilburg C; Yancey T; Weigel B; Norga K; Reaman G; Vassal G
    Eur J Cancer; 2020 Mar; 127():52-66. PubMed ID: 31986450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient".
    Bersanelli M; Cortellini A; Buti S
    Hum Vaccin Immunother; 2021 Jul; 17(7):1930-1934. PubMed ID: 33427023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New frontiers in oncology: Immune checkpoint inhibitors in combination therapy.
    Romano G; Gawlinski A
    Drugs Today (Barc); 2017 Feb; 53(2):103-115. PubMed ID: 28387388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
    Thompson JA; Schneider BJ; Brahmer J; Achufusi A; Armand P; Berkenstock MK; Bhatia S; Budde LE; Chokshi S; Davies M; Elshoury A; Gesthalter Y; Hegde A; Jain M; Kaffenberger BH; Lechner MG; Li T; Marr A; McGettigan S; McPherson J; Medina T; Mohindra NA; Olszanski AJ; Oluwole O; Patel SP; Patil P; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wang Y; Zaha VG; Lyons M; Dwyer M; Hang L
    J Natl Compr Canc Netw; 2022 Apr; 20(4):387-405. PubMed ID: 35390769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Immunotherapy for Acute Myeloid Leukemia.
    Tabata R; Chi S; Yuda J; Minami Y
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Expanding Role for Immunotherapy in Colorectal Cancer.
    Bever KM; Le DT
    J Natl Compr Canc Netw; 2017 Mar; 15(3):401-410. PubMed ID: 28275038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art.
    Le Saux O; Lounici Y; Wajda P; Barrin S; Caux C; Dubois B; Ray-Coquard I
    Crit Rev Oncol Hematol; 2021 Jan; 157():103172. PubMed ID: 33278676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment].
    Szekanecz É; Szekanecz Z
    Orv Hetil; 2019 Jun; 160(23):887-895. PubMed ID: 31155880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.